Table Graph
      published meta-analysis   sensitivity analysis   studies

anti-inflammatory therapies in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsCOL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41] 0.24[0.01; 5.41]COL-COVID (Pascual-Figal), 202110%103NAnot evaluable deathsdetailed resultsCOL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41] Lopes MIF, 2020 1.06 [0.02; 56.61] 0.42[0.04; 4.91]COL-COVID (Pascual-Figal), 2021, Lopes MIF, 202020%138moderatenot evaluable clinical deteriorationdetailed resultsCOL-COVID (Pascual-Figal), 2021 0.38 [0.09; 1.58] Ravichandran, 2021 0.02 [0.00; 0.36] 0.12[0.01; 1.91]COL-COVID (Pascual-Figal), 2021, Ravichandran, 2021269%313moderatenot evaluable mechanical ventilationdetailed resultsCOL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41] 0.24[0.01; 5.41]COL-COVID (Pascual-Figal), 202110%103NAnot evaluable radiologic improvement (14-day)detailed resultsRashad (CLARI vs SoC), 2021 2.87 [1.56; 5.28] 2.87[1.56; 5.28]Rashad (CLARI vs SoC), 202110%198NAnot evaluable viral clearance detailed resultsRavichandran, 2021 1.71 [0.80; 3.64] 1.71[0.80; 3.64]Ravichandran, 202110%122NAnot evaluable viral clearance by day 7detailed resultsRavichandran, 2021 1.71 [0.80; 3.64] 1.71[0.80; 3.64]Ravichandran, 202110%122NAnot evaluable ICU admissiondetailed resultsCOL-COVID (Pascual-Figal), 2021 0.47 [0.08; 2.69] 0.47[0.08; 2.69]COL-COVID (Pascual-Figal), 202110%103NAnot evaluable serious adverse eventsdetailed resultsCOL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41] 0.24[0.01; 5.41]COL-COVID (Pascual-Figal), 202110%103NAnot evaluable adverse eventsdetailed resultsCOL-COVID (Pascual-Figal), 2021 1.72 [0.73; 4.08] Ravichandran, 2021 1.04 [0.02; 52.86] 1.68[0.72; 3.91]COL-COVID (Pascual-Figal), 2021, Ravichandran, 202120%313moderatenot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-05-06 16:07 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons